Global Vaccine Market, People Vaccinated, Administered, Immunization, By Disease, By End User, Companies

Global Vaccine Market, People Vaccinated, Administered, Immunization, By Disease, By End User, Companies

Table of Contents

1. Research Findings

2. Global – Vaccines Market and Forecast
2.1 Adult Vaccines Market
2.2 Pediatric (Infant) Vaccines Market

3. Global – Adult Vaccine vs. Pediatric Vaccine Market Share

4. Global – Vaccines Market Share and Forecast
4.1 Adult Vaccines Market Share
4.2 Pediatric (Infant) Vaccines Market Share

5. Global – Vaccinated People
5.1 Adult Immunized and Forecast
5.2 Vaccinated Infant (Pediatric)

6. Global – Vaccinated People Share
6.1 Vaccinated Adult Share
6.2 Vaccinated Infant (Pediatric) Share

7. Global – Doses of Vaccines Administered and Forecast
7.1 Doses of Adult Vaccines Administered
7.2 Doses of Infant (Pediatric) Vaccines Administered

8. Global – Doses of Vaccines Administered Share
8.1 Doses of Vaccines Administered to Adult Share
8.2 Doses of Vaccines Administered to Infant (Pediatric) Share

9. Global – Vaccine Companies Market Share and Forecast

10. Disease wise – Vaccines Market and Forecast
10.1 Influenza – Total Vaccines Market
10.1.1 Influenza – Adult Vaccines Market
10.1.2 Influenza – Pediatric (Infant) Vaccines Market
10.2 Cervical Cancer (HPV) – Vaccines Market
10.3 Zoster (Shingles) – Vaccines Market
10.4 MMR (Measles, Mumps, and Rubella Vaccine) – Total Vaccines Market
10.4.1 MMR – Adult Vaccines Market
10.4.2 MMR – Pediatric (Infant) Vaccines Market
10.5 Pneumococcal – Total Vaccines Market
10.5.1 Pneumococcal – Adult Vaccines Market
10.5.2 Pneumococcal – Pediatric (Infant) Vaccines Market
10.6 Meningococcal – Total Vaccines Market
10.6.1 Meningococcal – Adult Vaccines Market
10.6.2 Meningococcal – Pediatric (Infant) Vaccines Market
10.7 Hepatitis – Total Vaccines Market
10.7.1 Hepatitis – Adult Vaccines Market
10.7.2 Hepatitis – Pediatric (Infant) Vaccines Market
10.8 TdaP and DTaP – Total Vaccines Market
10.8.1 TdaP – Adult Vaccines Market
10.8.2 DTaP – Pediatric (Infant) Vaccines Market
10.9 Travel and Miscellaneous – Vaccines Market
10.10 Haemophilus Influenzae Type B (HIB) – Vaccines Market
10.11 Combos (Combination) – Vaccines Market
10.12 Polio – Vaccines Market
10.13 Rotavirus – Vaccines Market
10.14 Varicella – Vaccines Market
10.14.1 Varicella – Adult Vaccines Market
10.14.2 Varicella – Pediatric (Infant) Vaccines Market

11. Disease wise – Numbers of Vaccinated People & Forecast
11.1 Influenza – Total Number of Vaccinated People
11.1.1 Influenza – Number of Vaccinated Adults
11.1.2 Influenza – Number of Vaccinated Infants
11.2 Cervical Cancer (HPV) – Number of Vaccinated People
11.3 Zoster (Shingles) – Number of Vaccinated People
11.4 MMR – Total Number of Vaccinated People
11.4.1 MMR – Number of Vaccinated Adults
11.4.2 MMR – Number of Vaccinated Infants (Pediatric)
11.5 Pneumococcal – Total Number of Vaccinated People
11.5.1 Pneumococcal – Number of Vaccinated Adults
11.5.2 Pneumococcal – Number of Vaccinated Infants
11.6 Meningococcal – Total Number of Vaccinated People
11.6.1 Meningococcal – Number of Vaccinated Adults
11.6.2 Meningococcal – Number of Vaccinated Infants
11.7 Hepatitis – Total Number of Vaccinated People
11.7.1 Hepatitis – Number of Vaccinated Adults
11.7.2 Hepatitis – Number of Vaccinated Infants
11.8 TdaP and DTaP – Total Number of Vaccinated People
11.8.1 TdaP – Number of Vaccinated Adults
11.8.2 DTaP – Number of Vaccinated Infants
11.9 Hib (Haemophilus Influenzae Type B) – Number of Vaaccinated Infants
11.10 Combos (Combination Vaccines) – Number of Vaccinated Infants
11.11 Polio – Number of Infants Immunized and Forecast
11.12 Rotavirus – Number of Vaccinated Infants
11.13 Varicella – Total Number of Vaccinated People
11.13.1 Varicella – Number of Vaccinated Adults
11.13.2 Varicella – Number of Vaccinated Infants

12. Disease wise – Doses of Vaccines Administered and Forecast
12.1 Influenza – Doses of Vaccines Administered
12.1.1 Influenza – Doses of Adult Vaccines Administered
12.1.2 Influenza – Doses of Infant Vaccines Administered
12.2 Cervical Cancer (HPV) – Doses of Vaccines Administered
12.3 Zoster (Shingles) – Doses of Vaccines Administered
12.4 MMR – Doses of Vaccines Administered
12.4.1 MMR – Doses of Adult Vaccines Administered
12.4.2 MMR – Doses of Infant Vaccines Administered
12.5 Pneumococcal – Doses of Vaccines Administered
12.5.1 Pneumococcal – Doses of Adult Vaccines Administered
12.5.2 Pneumococcal – Doses of Infant Vaccines Administered and Forecast
12.6 Meningococcal – Doses of Vaccines Administered
12.6.1 Meningococcal – Doses of Adult Vaccines Administered
12.6.2 Meningococcal – Doses of Infant Vaccines Administered
12.7 Hepatitis – Doses of Vaccines Administered
12.7.1 Hepatitis – Doses of Adult Vaccines Administered
12.7.2 Hepatitis – Doses of Infant Vaccines Administered
12.8 TdaP and DTaP – Doses of Vaccines Administered
12.8.1 TdaP – Doses of Adult Vaccines Administered and Forecast
12.8.2 DTaP – Doses of Infant Vaccines Administered
12.9 Hib (Haemophilus Influenzae Type B) – Doses of Infant Vaccines Administered and Forecast
12.10 Polio – Doses of Infant Vaccines Administered
12.11 Rotavirus – Doses of Infant Vaccines Administered and Forecast
12.12 Varicella – Doses of Vaccines Administered
12.12.1 Varicella – Doses of Adult Vaccines Administered
12.12.2 Varicella – Doses of Infant Vaccines Administered

13. Disease wise - Immunization Profile
13.1 Immunization Coverage (%) in Infants
13.2 Global Immunization Profile
13.3 Regional Immunization Profile
13.3.1 Measles – Number of Reported Cases
13.3.2 Mumps – Number of Reported Cases
13.3.3 Rubella – Number of Reported Cases
13.3.4 Rubella (CRS) – Number of Reported Cases
13.3.5 Diphtheria – Number of Reported Cases
13.3.6 Tetanus (Neonatal) – Number of Reported Cases
13.3.7 Tetanus (Total) – Number of Reported Cases
13.3.8 Pertussis – Number of Reported Cases
13.3.9 Polio – Number of Reported Cases
13.3.10 Yellow Fever – Number of Reported Cases
13.3.11 Japanese encephalitis – Number of Reported Cases

14. Vaccines Key Players Sales and Forecast
14.1 GlaxoSmithKline, plc.’s Vaccines Sales
14.2 Merck & Co. Vaccines Sales
14.3 Sanofi Pasteur’s Vaccines Sales
14.4 Pfizer, Inc.’s Vaccines Sales
14.5 Global – Other Companies Vaccines Sales

15. Vaccines – Products and Pipeline
15.1 GSK Vaccine Product Pipeline
15.2 Merck Vaccine Product Pipeline
15.3 Sanofi Vaccine Product Pipeline
15.4 Pfizer Vaccine Product Pipeline

16. Top Mergers and Acquisitions in the Vaccine Industry

17. Vaccines and Regulator’s Interventions
17.1 Making and Meeting Standards of Quality and Safety
17.2 Vaccine Funding

18. Vaccine Market Drivers
18.1 Inclusion in National Immunization Schedule
18.2 Growing Immunization Coverage for HPV Vaccines
18.3 Increase in Prevalence of Infectious Diseases
18.4 Global Immunization Vision and Strategy (GIVS)
18.5 GAVI Model Fuelling Vaccine Manufacturers
18.5.1 The Partnership Model
18.5.2 The Business Model
18.6 Increasing Vaccine Availability in United States
18.7 The Vaccine Safety Data link Project
18.8 The Vaccine Injury Compensation Program
18.9 Transforming of Vaccine Technologies
18.10 Global Vaccine Action Plan by WHO (2011 - 2020)
18.11 Continuous Focus on Effective Communication Strategies

19. Vaccines Market Challenges
19.1 Hurdles to Optimal use of Licensed Vaccines
19.1.1 Technical Obstacles
19.1.2 Economic Obstacles
19.1.3 Cultural Obstacles
19.2 Complexity of Vaccine Development & Approval System Thwarts Product Development
19.2.1 Legal Obstacles
19.2.2 General Technical Barriers
19.2.3 Economic Barriers
19.2.4 Regulatory Barriers
19.3 Shortening the Timeline for Vaccine Development
19.4 Refusal/Resistance to Vaccination
19.4.1 Vaccine Adverse Event Reporting System
19.5 Vaccine Shortages and Delays
19.6 Obstacles in Vaccine Research & Development
19.7 Barriers to New Entrants in the Vaccines Market

Lists of Tables:

Table 2‑1: Vaccine Recommendations
Table 2‑2: Other Recommended Vaccines
Table 6‑1: Global – Vaccinated People Share (Percent), 2011 - 2017
Table 6‑2: Global – Forecast for Vaccinated People Share (Percent), 2018 – 2024
Table 13‑1: Worldwide Immunization Coverage (%) in Infants, 2005- 2010
Table 13‑2: Worldwide Immunization Coverage (%) in Infants, 2011- 2016
Table 13‑3: Vaccines – Number of Reported Cases, 2011 – 2017
Table 13‑4: Measles – Number of Reported Cases, 2001 – 2016
Table 13‑5: Mumps – Number of Reported Cases, 2001 - 2016
Table 13‑6: Rubella – Number of Reported Cases, 2001 - 2016
Table 13‑7: Rubella (CRS) – Number of Reported Cases, 2001 - 2016
Table 13‑8: Diphtheria – Number of Reported Cases, 2001 - 2016
Table 13‑9: Tetanus (Neonatal) – Number of Reported Cases, 2001 – 2016
Table 13‑10: Tetanus (Total) – Number of Reported Cases, 2001 - 2016
Table 13‑11: Pertussis – Number of Reported Cases, 2001 - 2016
Table 13‑12: Polio – Number of Reported Cases, 2001 - 2016
Table 13‑13: Yellow Fever – Number of Reported Cases, 2001 - 2016
Table 13‑14: Japanese Encephalitis – Number of Reported Cases Reported, 2006 - 2016
Table 15‑1: Merck Vaccine Product Pipeline
Table 15‑2: Sanofi Vaccine Product Pipeline
Table 15‑3: Pfizer Vaccine Product Pipeline
Table 16‑1: Vaccine Mergers & Acquisitions
Table 18‑1: United States Immunization Schedule
Table 18‑2: Afghanistan Immunization Schedule
Table 18‑3: Norway Immunization Schedule
Table 18‑4: India Immunization Schedule
Table 18‑5: Vietnam Immunization Schedule
Table 18‑6: Worldwide – Total Future Deaths Averted through Vaccination (Million), 2011 – 2020
Table 18‑7: Goal-Level Indicators, 2015 & 2020
Table 18‑8: Improvement Strategies or Requirements – the Joint Commission and the Project’s Collaborating Organizations

List of Figures:

Figure 2‑1: Global – Vaccines Market (Billion US$), 2011 - 2017
Figure 2‑2: Global – Forecast for Vaccines Market (Billion US$), 2018 – 2024
Figure 2‑3: Global – Adult Vaccines Market (Billion US$), 2011 – 2017
Figure 2‑4: Global – Forecast for Adult Vaccines Market (Billion US$), 2018 – 2024
Figure 2‑5: Global – Pediatric (Infant) Vaccines Market (Billion US$), 2011 – 2017
Figure 2‑6: Global – Forecast for Pediatric (Infant) Vaccines Market (Billion US$), 2018 – 2024
Figure 3‑1: Global – Adult Vs. Pediatric Vaccine Market Share, 2011- 2017
Figure 3‑2: Global – Forecast for Adult Vs. Pediatric Vaccine Market Share, 2018 - 2024
Figure 4‑1: Global – Vaccines Market Share (Percent), 2011 - 2017
Figure 4‑2: Global – Forecast for Vaccines Market Share (Percent), 2018 - 2024
Figure 4‑3: Global – Adult Vaccines Market Share (Percent), 2011 - 2017
Figure 4‑4: Global – Forecast for Adult Vaccines Market Share (Percent), 2018 - 2024
Figure 4‑5: Global – Pediatric (Infant) Vaccines Market Share (Percent), 2011 - 2017
Figure 4‑6: Global – Forecast for Pediatric (Infant) Vaccines Market Share (Percent), 2018 - 2024
Figure 5‑1: Global – Vaccinated People (Million), 2011 - 2017
Figure 5‑2: Global – Forecast for Vaccinated People (Million), 2018 - 2024
Figure 5‑3: Global – Number of Vaccinated Adult (Million), 2011 – 2017
Figure 5‑4: Global – Forecast for Number of Vaccinated Adult (Million), 2018 – 2024
Figure 5‑5: Global – Number of Vaccinated Infant (Pediatric) (Million), 2011 - 2017
Figure 5‑6: Global – Forecast for Number of Vaccinated Infant (Pediatric) (Million), 2018 – 2024
Figure 6‑1: Global – Vaccinated Adult Share (Percent), 2011 - 2017
Figure 6‑2: Global – Forecast for Vaccinated Adult Share (Percent), 2018 – 2024
Figure 6‑3: Global – Vaccinated Infant (Pediatric) Share (Percent), 2011 – 2017
Figure 6‑4: Global – Forecast for Vaccinated Infant (Pediatric) Share (Percent), 2018 – 2024
Figure 7‑1: Global – Doses of Vaccines Administered (Million), 2011 - 2017
Figure 7‑2: Global – Forecast for Doses of Vaccines Administered (Million), 2018 – 2024
Figure 7‑3: Global – Doses of Adult Vaccines Administered (Million), 2011 - 2017
Figure 7‑4: Global – Forecast for Doses of Adult Vaccines Administered (Million), 2018 - 2024
Figure 7‑5: Global – Doses of Pediatric (Infant) Vaccines Administered (Million), 2011 - 2017
Figure 7‑6: Global – Forecast for Doses of Pediatric (Infant) Vaccines Administered (Million), 2018 - 2024
Figure 8‑1: Global – Doses of Vaccines Administered Share (Percent), 2011 - 2017
Figure 8‑2: Global – Forecast for Doses of Vaccines Administered Share (Percent), 2018 - 2024
Figure 8‑3: Global – Doses of Vaccines Administered to Adult Share (Percent), 2011 - 2017
Figure 8‑4: Global – Forecast for Doses of Vaccines Administered to Adult Share (Percent), 2018 - 2024
Figure 8‑5: Global – Doses of Vaccines Administered to Pediatric (Infant) Share (Percent), 2011 - 2017
Figure 8‑6: Global – Forecast for Doses of Vaccines Administered to Pediatric (Infant) Share (Percent), 2018 - 2024
Figure 9‑1: Global – Key Players Vaccines Market Share (Percent), 2011 - 2017
Figure 9‑2: Global – Forecast for Key Players Vaccines Market Share (Percent), 2018 - 2024
Figure 10‑1: Influenza – Total Vaccines Market (Billion US$), 2011 - 2017
Figure 10‑2: Influenza – Forecast for Total Vaccines Market (Billion US$), 2018 - 2024
Figure 10‑3: Influenza – Adult Vaccines Market (Billion US$), 2011 - 2017
Figure 10‑4: Influenza – Forecast for Adult Vaccines Market (Billion US$), 2018 – 2024
Figure 10‑5: Influenza – Pediatric (Infant) Vaccines Market (Million US$), 2011 - 2017
Figure 10‑6: Influenza – Forecast for Pediatric (Infant) Vaccines Market (Million US$), 2018 - 2024
Figure 10‑7: Cervical Cancer (HPV) – Vaccines Market (Billion US$), 2011 – 2017
Figure 10‑8: Cervical Cancer (HPV) – Forecast for Vaccines Market (Billion US$), 2018 - 2024
Figure 10‑9: Zoster (Shingles) – Vaccines Market (Billion US$), 2011 - 2017
Figure 10‑10: Zoster (Shingles) – Forecast for Vaccines Market (Billion US$), 2018 - 2024
Figure 10‑11: MMR – Total Vaccines Market (Billion US$), 2011 - 2017
Figure 10‑12: MMR – Forecast for Total Vaccines Market (Billion US$), 2018 – 2024
Figure 10‑13: MMR – Adult Vaccines Market (Million US$), 2011 – 2017
Figure 10‑14: MMR – Forecast for Adult Vaccines Market (Million US$), 2018 – 2024
Figure 10‑15: MMR – Pediatric (Infant) Vaccines Market (Million US$), 2011 – 2017
Figure 10‑16: MMR – Forecast for Pediatric (Infant) Vaccines Market (Million US$), 2018 - 2024
Figure 10‑17: Pneumococcal – Total Vaccines Market (Billion US$), 2011 - 2017
Figure 10‑18: Pneumococcal – Forecast for Total Vaccines Market (Billion US$), 2018 - 2024
Figure 10‑19: Pneumococcal – Adult Vaccines Market (Billion US$), 2011 - 2017
Figure 10‑20: Pneumococcal – Forecast for Adult Vaccines Market (Billion US$), 2018 – 2024
Figure 10‑21: Pneumococcal – Pediatric (Infant) Vaccines Market (Billion US$), 2011 - 2017
Figure 10‑22: Pneumococcal – Forecast for Pediatric (Infant) Vaccines Market (Billion US$), 2018 - 2024
Figure 10‑23: Areas with frequent epidemics of meningococcal meningitis
Figure 10‑24: Meningococcal – Total Vaccines Market (Million US$), 2011 – 2017
Figure 10‑25: Meningococcal – Forecast for Total Vaccines Market (Million US$), 2018 – 2024
Figure 10‑26: Meningococcal – Adult Vaccines Market (Million US$), 2011 – 2017
Figure 10‑27: Meningococcal – Forecast for Adult Vaccines Market (Million US$), 2018 - 2024
Figure 10‑28: Meningococcal – Pediatric (Infant) Vaccines Market (Million US$), 2011 - 2017
Figure 10‑29: Meningococcal – Forecast for Pediatric (Infant) Vaccines Market (Million US$), 2018 - 2024
Figure 10‑30: Hepatitis – Total Vaccines Market (Billion US$), 2011 - 2017
Figure 10‑31: Hepatitis – Forecast for Total Vaccines Market (Billion US$), 2018 - 2024
Figure 10‑32: Hepatitis – Adult Vaccines Market (Billion US$), 2011 - 2017
Figure 10‑33: Hepatitis – Forecast for Adult Vaccines Market (Billion US$), 2018 - 2024
Figure 10‑34: Hepatitis – Pediatric (Infant) Vaccines Market (Million US$), 2011 - 2017
Figure 10‑35: Hepatitis – Forecast for Pediatric (Infant) Vaccines Market (Million US$), 2018 - 2024
Figure 10‑36: TdaP and DTaP – Total Vaccines Market (Million US$), 2011 - 2017
Figure 10‑37: TdaP and DTaP – Forecast for Total Vaccines Market (Million US$), 2018 - 2024
Figure 10‑38: TdaP – Adult Vaccines Market (Million US$), 2011 - 2017
Figure 10‑39: TdaP – Forecast for Adult Vaccines Market (Million US$), 2018 - 2024
Figure 10‑40: DTaP – Pediatric (Infant) Vaccines Market (Million US$), 2011 - 2017
Figure 10‑41: DTaP – Forecast for Pediatric (Infant) Vaccines Market (Million US$), 2018 - 2024
Figure 10‑42: Travel and Miscellaneous – Vaccines Market (Billion US$), 2011 - 2017
Figure 10‑43: Travel and Miscellaneous – Forecast for Vaccines Market (Billion US$), 2018 - 2024
Figure 10‑44: Haemophilus Influenzae Type B (HIB) – Vaccines Market (Million US$), 2011 - 2017
Figure 10‑45: Haemophilus Influenzae Type B (HIB) – Forecast for Vaccines Market (Million US$), 2018 - 2024
Figure 10‑46: Combos (Combination) – Vaccines Market (Billion US$), 2011 - 2017
Figure 10‑47: Combos (Combination) – Forecast for Vaccines Market (Billion US$), 2018 - 2024
Figure 10‑48: Polio – Vaccines Market (Million US$), 2011 - 2017
Figure 10‑49: Polio – Forecast for Vaccines Market (Million US$), 2018 - 2024
Figure 10‑50: Rotavirus Deaths Under Five Years of Age per 100 000 Population Figure 10‑51: Ten Countries Accounting for Almost Two Thirds of All Deaths, 2013
Figure 10‑52: Rotavirus – Vaccines Market (Million US$), 2011 - 2017
Figure 10‑53: Rotavirus – Forecast for Vaccines Market (Million US$), 2018 - 2024
Figure 10‑54: Varicella – Total Vaccines Market (Billion US$), 2011 - 2017
Figure 10‑55: Varicella – Forecast for Total Vaccines Market (Billion US$), 2018 – 2024
Figure 10‑38: Varicella – Adult Vaccines Market (Million US$), 2011 - 2017
Figure 10‑39: Varicella – Forecast for Adult Vaccines Market (Million US$), 2018 - 2024
Figure 10‑40: Varicella – Pediatric (Infant) Vaccines Market (Million US$), 2011 - 2017
Figure 10‑41: Varicella – Forecast for Pediatric (Infant) Vaccines Market (Million US$), 2018 - 2024
Figure 11‑1: Influenza – Total Number of Vaccinated People (Million), 2011 - 2017
Figure 11‑2: Influenza – Forecast for Total Number of Vaccinated People (Million), 2018 – 2024
Figure 11‑3: Influenza – Number of Vaccinated Adults (Million), 2011 - 2017
Figure 11‑4: Influenza – Forecast for Number of Vaccinated Adults (Million), 2018 - 2024
Figure 11‑5: Influenza – Number of Vaccinated Infants (Million), 2011 - 2017
Figure 11‑6: Influenza – Forecast for Number of Vaccinated Infants (Million), 2018 - 2024
Figure 11‑7: Cervical Cancer – Number of Vaccinated People (Million), 2011 - 2017
Figure 11‑8: Cervical Cancer – Forecast for Number of Vaccinated People (Million), 2018 - 2024
Figure 11‑9: Zoster (Shingles) – Number of Vaccinated People (Million), 2011 - 2017
Figure 11‑10: Zoster (Shingles) – Forecast for Number of Vaccinated People (Million), 2018 - 2024
Figure 11‑11: MMR – Total Number of Vaccinated People (Million), 2011 - 2017
Figure 11‑12: MMR – Forecast for Total Number of Vaccinated People (Million), 2018 - 2024
Figure 11‑13: MMR – Number of Vaccinated Adults (Million), 2011 - 2017
Figure 11‑14: MMR – Forecast for Number of Vaccinated Adults (Million), 2018 - 2024
Figure 11‑15: MMR – Number of Vaccinated Infants (Pediatric) (Million), 2011 - 2017
Figure 11‑16: MMR – Forecast for Number of Vaccinated Infants (Pediatric) (Million), 2018 - 2024
Figure 11‑17: Pneumococcal – Total Number of Vaccinated People (Million), 2011 - 2017
Figure 11‑18: Pneumococcal – Forecast for Total Number of Vaccinated People (Million), 2018 - 2024
Figure 11‑19: Pneumococcal – Number of Vaccinated Adults (Million), 2011 - 2017
Figure 11‑20: Pneumococcal – Forecast for Number of Vaccinated Adults (Million), 2018 - 2024
Figure 11‑21: Pneumococcal – Number of Vaccinated Infants (Million), 2011 - 2017
Figure 11‑22: Pneumococcal – Forecast for Number of Vaccinated Infants (Million), 2018 - 2024
Figure 11‑23: Meningococcal – Total Number of People Immunized (Million), 2011 – 2017
Figure 11‑24: Meningococcal – Forecast for Total Number of Vaccinated People (Million), 2018 - 2024
Figure 11‑25: Meningococcal – Number of Vaccinated Adults (Million), 2011 - 2017
Figure 11‑26: Meningococcal – Forecast for Number of Vaccinated Adults (Million), 2018 - 2024
Figure 11‑27: Meningococcal – Number of Vaccinated Infants (Million), 2011 - 2017
Figure 11‑28: Meningococcal – Forecast for Number of Vaccinated Infants (Million), 2018 - 2024
Figure 11‑29: Hepatitis – Total Number of Vaccinated People (Million), 2011 - 2017
Figure 11‑30: Hepatitis – Forecast for Total Number of vaccinated People (Million), 2018 - 2024
Figure 11‑31: Hepatitis – Number of Vaccinated Adults (Million), 2011 - 2017
Figure 11‑32: Hepatitis – Forecast for Number of Adults Immunized (Thousand), 2018 - 2024
Figure 11‑33: Hepatitis – Number of Vaccinated Infants (Million), 2011 - 2017
Figure 11‑34: Hepatitis – Forecast for Number of Vaccinated Infants (Million), 2018 - 2024
Figure 11‑35: TdaP and DTaP – Total Number of Vaccinated People (Million), 2011 - 2017
Figure 11‑36: TdaP and DTaP – Forecast for Total Number of Vaccinated People (Million), 2018 - 2024
Figure 11‑37: TdaP – Number of Vaccinated Adults (Million), 2011 - 2017
Figure 11‑38: TdaP – Number of Vaccinated Adults (Million), 2018 - 2024
Figure 11‑39: DTaP – Number of Vaccinated Infants (Million), 2011 - 2017
Figure 11‑40: DTaP – Forecast for Number of Vaccinated Infants (Million), 2018 - 2024
Figure 11‑41: Hib (Haemophilus Influenzae Type B) – Number of Vaccinated Infants (Million), 2011 - 2017
Figure 11‑42: Hib (Haemophilus Influenzae Type B) – Forecast for Number of Vaccinated Infants (Million), 2018 - 2024
Figure 11‑43: Combos (Combination Vaccines) – Number of Vaccinated Infants (Million), 2011 - 2017
Figure 11‑44: Combos (Combination Vaccines) – Forecast for Number of Vaccinated Infants (Million), 2018 - 2024
Figure 11‑45: Polio – Number of Infants Immunized (Million), 2011 - 2017
Figure 11‑46: Polio – Forecast for Number of Vaccinated Infants (Million), 2018 - 2024
Figure 11‑47: Rotavirus – Number of Infants Immunized (Million), 2011 - 2017
Figure 11‑48: Rotavirus – Forecast for Number of Infants Immunized (Million), 2018 - 2024
Figure 11‑35: Varicella – Total Number of Vaccinated People (Million), 2011 - 2017
Figure 11‑36: Varicella – Forecast for Total Number of Vaccinated People (Million), 2018 - 2024
Figure 11‑37: Varicella – Number of Vaccinated Adults (Million), 2011 - 2017
Figure 11‑38: Varicella – Number of Vaccinated Adults (Million), 2018 - 2024
Figure 11‑39: Varicella – Number of Vaccinated Infants (Million), 2011 - 2017
Figure 11‑40: Varicella – Forecast for Number of Vaccinated Infants (Million), 2018 - 2024
Figure 12‑1: Influenza – Doses of Vaccines Administered (Million), 2011 - 2017
Figure 12‑2: Influenza – Forecast for Doses of Vaccines Administered (Million), 2018 - 2024
Figure 12‑3: Influenza – Doses of Adult Vaccines Administered (Million), 2011 - 2017
Figure 12‑4: Influenza – Forecast for Doses of Adult Vaccines Administered (Million), 2018 - 2024
Figure 12‑5: Influenza – Doses of Infant Vaccines Administered (Million), 2011 - 2017
Figure 12‑6: Influenza – Forecast for Doses of Infant Vaccines Administered (Million), 2018 - 2024
Figure 12‑7: Cervical Cancer (HPV) – Doses of Vaccines Administered (Million), 2011 - 2017
Figure 12‑8: Cervical Cancer (HPV) – Forecast for Doses of Vaccines Administered (Million), 2018 - 2024
Figure 12‑9: Zoster (Shingles) – Doses of Vaccines Administered (Million), 2011 - 2017
Figure 12‑10: Zoster (Shingles) – Forecast for Doses of Vaccines Administered (Million), 2018 - 2024
Figure 12‑11: MMR – Doses of Vaccines Administered (Million), 2011 - 2017
Figure 12‑12: MMR – Forecast for Doses of Vaccines Administered (Million), 2018 - 2024
Figure 12‑13: MMRV – Doses of Adult Vaccines Administered (Million), 2011 - 2017
Figure 12‑14: MMRV – Forecast for Doses of Adult Vaccines Administered (Million), 2018 - 2024
Figure 12‑15: MMR – Doses of Infant Vaccines Administered (Million), 2011 - 2017
Figure 12‑16: MMR – Forecast for Doses of Infant Vaccines Administered (Million), 2018 - 2024
Figure 12‑17: Pneumococcal – Doses of Vaccines Administered (Million), 2011 - 2017
Figure 12‑18: Pneumococcal – Forecast for Doses of Vaccines Administered (Million), 2018 - 2024
Figure 12‑19: Pneumococcal – Doses of Adult Vaccines Administered (Million), 2011 - 2017
Figure 12‑20: Pneumococcal – Forecast for Doses of Adult Vaccines Administered (Million), 2018 - 2024
Figure 12‑21: Pneumococcal – Doses of Infant Vaccines Administered (Million), 2011 - 2017
Figure 12‑22: Pneumococcal – Forecast for Doses of Infant Vaccines Administered (Million), 2018 - 2024
Figure 12‑23: Meningococcal – Doses of Vaccines Administered (Million), 2011 - 2017
Figure 12‑24: Meningococcal – Forecast for Doses of Vaccines Administered (Million), 2018 - 2024
Figure 12‑25: Meningococcal – Doses of Adult Vaccines Administered (Million), 2011 - 2017
Figure 12‑26: Meningococcal – Forecast for Doses of Adult Vaccines Administered (Million), 2018 - 2024
Figure 12‑27: Meningococcal – Doses of Infant Vaccines Administered (Million), 2011 - 2017
Figure 12‑28: Meningococcal – Forecast for Doses of Infant Vaccines Administered (Million), 2018 - 2024
Figure 12‑29: Hepatitis – Doses of Vaccines Administered (Million), 2011 - 2017
Figure 12‑30: Hepatitis – Forecast for Doses of Vaccines Administered (Million), 2018 - 2024
Figure 12‑31: Hepatitis – Doses of Adult Vaccines Administered (Million), 2011 - 2017
Figure 12‑32: Hepatitis – Forecast for Doses of Adult Vaccines Administered (Million), 2018 - 2024
Figure 12‑33: Hepatitis – Doses of Infant Vaccines Administered (Million), 2011 - 2017
Figure 12‑34: Hepatitis – Forecast for Doses of Infant Vaccines Administered (Million), 2018 - 2024
Figure 12‑35: TdaP and DTaP – Doses of Vaccines Administered (Million), 2011 - 2017
Figure 12‑36: TdaP and DTaP – Forecast for Doses of Vaccines Administered (million), 2018 - 2024
Figure 12‑37: TdaP – Doses of Adult Vaccines Administered (Million), 2011 - 2017
Figure 12‑38: TdaP – Forecast for Doses of Adult Vaccines Administered (Million), 2018 - 2024
Figure 12‑39: DTaP – Doses of Infant Vaccines Administered (Million), 2011 - 2017
Figure 12‑40: DTaP – Forecast for Doses of Infant Vaccines Administered (Million), 2018 - 2024
Figure 12‑41: Hib (Haemophilus Influenzae Type B) – Doses of Infant Vaccines Administered (Million), 2011 - 2017
Figure 12‑42: Hib (Haemophilus Influenzae Type B) – Forecast for Doses of Infant Vaccines Administered (Million), 2018 - 2024
Figure 12‑43: Polio – Doses of Infant Vaccines Administered (Million), 2011 - 2017
Figure 12‑44: Polio – Forecast for Doses of Infant Vaccines Administered (Million), 2018 - 2024
Figure 12‑45: Rotavirus – Doses of Infant Vaccines Administered (Million), 2011 - 2017
Figure 12‑46: Rotavirus – Forecast for Doses of Infant Vaccines Administered (Million), 2018 - 2024
Figure 12‑35: Varicella – Total Doses of Vaccines Administered (Million), 2011 - 2017
Figure 12‑36: Varicella – Forecast for Total Doses of Vaccines Administered (million), 2018 - 2024
Figure 12‑37: Varicella – Doses of Adult Vaccines Administered (Million), 2011 - 2017
Figure 12‑38: Varicella – Forecast for Doses of Adult Vaccines Administered (Million), 2018 - 2024
Figure 12‑47: Varicella – Doses of Infant Vaccines Administered (Million), 2011 - 2017
Figure 12‑48: Varicella – Forecast for Doses of Infant Vaccines Administered (Million), 2018 - 2024
Figure 14‑1: Global - GlaxoSmithKline, plc.’s Vaccines Sales (Billion US$), 2011 - 2017
Figure 14‑2: Global – Forecast for GlaxoSmithKline, plc.’s Vaccines Sales (Billion US$), 2018 - 2024
Figure 14‑3: Global - Merck & Co. Vaccines Sales (Billion US$), 2011 - 2017
Figure 14‑4: Global – Forecast for Merck & Co. Vaccines Sales (Billion US$), 2018 - 2024
Figure 14‑5: Global - Sanofi Pasteur’s Vaccines Sales (Billion US$), 2011 - 2017
Figure 14‑6: Global – Forecast for Sanofi Pasteur’s Vaccines Sales (Billion US$), 2018 - 2024
Figure 14‑7: Global - Pfizer, Inc.’s Vaccines Sales (Billion US$), 2011 - 2017
Figure 14‑8: Global – Forecast for Pfizer, Inc.’s Vaccines Sales (Billion US$), 2018 - 2024
Figure 14‑9: Global – Other Companies Vaccines Sales (Billion US$), 2011 - 2017
Figure 14‑10: Global – Forecast for Other Companies Vaccines Sales (Billion US$), 2018 - 2024
Figure 15‑1: GSK Vaccine Product Pipeline
Figure 18‑1: Countries with HPV Vaccination Program listed on their National Immunization Program (NIP) Schedule
Figure 18‑2: Number of Cases of Diphtheria, Pertussis, Tetnaus & Measles by Major Region Worldwide, 2013
Figure 18‑3: Vaccines Procured by UNICEF: Industrialized and Emerging Market Country Manufacturers
Figure 18‑4: Vaccines procured by UNICEF: Industrialized and Emerging Market Country Manufacturers
Figure 18‑5: US Retail Clinics Expected to Surge by 2017

X

• Clinical Results in Diabetics To Be Boosted By Smart Artificial Beta Cells

For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…

• High-speed Data Transmission And High Volume Needs Propel Fiber Optic Connectors Market

Fiber optic connectors are a substantial fragment of the global telecommunication industry. Optical fibers are joined using fiber optic connectors, which allow the light conduction between two consecutive optical fibers. An additional im…

• Extensive Use of Digital Technologies for Diagnostic Applications To Boost Global Optical Imaging Market

The global optical imaging system market is predicted to reach US$ 3 billion by 2024. It is expected to grow at a stable rate and will post a CAGR of more than 8% in the coming years. The growing market infiltration of digital …

• Foremost Trends In Global Pet Care Market

The global pet care market is foretold to improve in the forthcoming years as matched to the preceding years and will showcase better sales in various market segments. It is estimated that the global pet care market will grow at a CAGR o…

• China To Review Its Food Security Laws

China has arisen as the globe’s firmest developing economy. In addition, China brags about the biggest population pool in the world. In recent times, the one child policy in the republic was terminated. This is anticipated to upsur…

Global Antioxidant Vitamins Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 100

The global Antioxidant Vitamins market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ millio......

Global Clavulanate Potassium Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 86

The global Clavulanate Potassium market was valued at US$ 446.6 million in 2023 and is anticipated to reach US$ 637.2 million by 2030, witnessing a CAGR of 5.2% during The forecast period 2024-2030. North American market for Clavulanate Potassium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Clavulanate Potassium is estimated to increase from $ million in 2023......

Global Amoxicillin Sodium Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 84

The global Amoxicillin Sodium market was valued at US$ 460.9 million in 2023 and is anticipated to reach US$ 735.1 million by 2030, witnessing a CAGR of 7.0% during The forecast period 2024-2030. North American market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach......

Global Melatonin Supplements Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 106

The global Melatonin Supplements market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ mil......

Global Sleeping Pills (Prescription Drugs) Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 93

The global Sleeping Pills (Prescription Drugs) market was valued at US$ 1022.3 million in 2023 and is anticipated to reach US$ 1437.8 million by 2030, witnessing a CAGR of 4.9% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical......

Global Sleeping Pills Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 94

The global Sleeping Pills market was valued at US$ 2042.3 million in 2023 and is anticipated to reach US$ 2979.5 million by 2030, witnessing a CAGR of 3.8% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estim......

Global Zinc Oral Drops Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85

The global Zinc Oral Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a......

Global Zinc Drops Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85

The global Zinc Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % duri......

Global Anti-Infectives Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 78

The global Anti-Infectives market was valued at US$ 22700 million in 2023 and is anticipated to reach US$ 27480 million by 2030, witnessing a CAGR of 2.3% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estima......

We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s. Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors. Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business. Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision. Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us. Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done. Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )

• Ad Hoc
• Pay - as - you - go / Bucket Subscriptions
• Fixed Cost for #of reports
• Customize / Personalize as per your needs